BNTX
NASDAQBioNTech SE
Price$92.03-1.15 (-1.23%)
01:30 PM07:45 PM
News · 26 weeks64+50%
2026-04-122026-10-04
Mix3590d
- Insider13(37%)
- SEC Filings9(26%)
- Other8(23%)
- Earnings2(6%)
- Analyst2(6%)
- Leadership1(3%)
Latest news
25 items- ANALYSTArgus initiated coverage on BioNTechArgus initiated coverage of BioNTech with a rating of Hold
- INSIDERSEC Form 4 filed by BioNTech SE4 - BioNTech SE (0001776985) (Issuer)
- INSIDERSEC Form 4 filed by BioNTech SE4 - BioNTech SE (0001776985) (Issuer)
- INSIDERChief Executive Officer Sahin Ugur sold $3,301,068 worth of Ordinary Shares (34,000 units at $97.09) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 180,209 units (SEC Form 4)4 - BioNTech SE (0001776985) (Issuer)
- INSIDERChief Executive Officer Sahin Ugur sold $6,480,659 worth of Ordinary Shares (66,000 units at $98.19) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 214,209 units (SEC Form 4)4 - BioNTech SE (0001776985) (Issuer)
- INSIDERChief Executive Officer Sahin Ugur sold $6,012,500 worth of Ordinary Shares (61,000 units at $98.57) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 280,209 units (SEC Form 4)4 - BioNTech SE (0001776985) (Issuer)
- INSIDERChief Executive Officer Sahin Ugur sold $6,842,742 worth of Ordinary Shares (69,000 units at $99.17) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 341,209 units (SEC Form 4)4 - BioNTech SE (0001776985) (Issuer)
- INSIDERChief Executive Officer Sahin Ugur sold $7,860,757 worth of Ordinary Shares (79,000 units at $99.50) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 410,209 units (SEC Form 4)4 - BioNTech SE (0001776985) (Issuer)
- INSIDERChief Executive Officer Sahin Ugur sold $6,239,071 worth of Ordinary Shares (64,000 units at $97.49) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 489,209 units (SEC Form 4)4 - BioNTech SE (0001776985) (Issuer)
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- INSIDERChief Executive Officer Sahin Ugur sold $4,721,976 worth of Ordinary Shares (49,000 units at $96.37) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 553,209 units (SEC Form 4)4 - BioNTech SE (0001776985) (Issuer)
- PRA $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral ThreatNEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can emerge quickly, cross borders and overwhelm healthcare systems before effective therapies are ready. That creates a large and growing commercial opportunity for companies working on drugs that can actually stop viral diseases rather than simply manage their symptoms. The global antiviral drugs market was valued at roughly $42.3 billion in 2025 and is projected to reach approximately $57.8 billion by 2034. But those numbers only tell part of the story. The bigger opportunity may be
- INSIDERChief Executive Officer Sahin Ugur sold $8,439,336 worth of Ordinary Shares (86,000 units at $98.13) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 602,209 units (SEC Form 4)4 - BioNTech SE (0001776985) (Issuer)
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PRBioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer PatientsGotistobart continues to show potential as chemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current standard of care treatments is less than one year1Gotistobart demonstrated a median overall survival of 18.5 months compared to 10.0 months with standard-of-care chemotherapy in updated data from stage 1 of the PRESERVE-003 Phase 3 clinical trial, nearly doubling median survival in this patient populationFindings are consistent with gotistobart’s differentiated mechanism of action as an investigational immunomodulator that selectively enhances regulatory T cell depletion through CTL
- INSIDERChief Executive Officer Sahin Ugur sold $1,974,287 worth of Ordinary Shares (20,500 units at $96.31) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 688,209 units (SEC Form 4)4 - BioNTech SE (0001776985) (Issuer)
- INSIDERChief Executive Officer Sahin Ugur sold $7,190,663 worth of Ordinary Shares (73,000 units at $98.50) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 708,709 units (SEC Form 4)4 - BioNTech SE (0001776985) (Issuer)
- INSIDERChief Executive Officer Sahin Ugur sold $7,889,055 worth of Ordinary Shares (76,500 units at $103.12) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 781,709 units (SEC Form 4)4 - BioNTech SE (0001776985) (Issuer)
- ANALYSTBioNTech downgraded by BMO Capital Markets with a new price targetBMO Capital Markets downgraded BioNTech from Outperform to Market Perform and set a new price target of $105.00
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PRPfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variantsShipping will begin immediately to ensure rapid access to this season’s vaccine NEW YORK and MAINZ, GERMANY, August 27, 2026 — Pfizer Inc. (NYSE:PFE, "Pfizer")) and BioNTech SE (NASDAQ:BNTX, "BioNTech")) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at
- PRA Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest OpportunityNEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - If watching where cancer treatment is headed, mRNA cancer vaccines are hard to ignore—especially in lung cancer. The basic idea is surprisingly straightforward: instead of giving the immune system a one-size-fits-all treatment, an mRNA vaccine can be designed to teach it what a particular tumor looks like and help it go after those cancer cells. That matters in lung cancer because every tumor can be different, and some eventually learn how to get around existing treatments. Researchers are now looking at whether personalized mRNA vaccines can work alongside today’s immunotherapies to give the immune system a
- SECSEC Form 6-K filed by BioNTech SE6-K - BioNTech SE (0001776985) (Filer)
- PRBioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNTech’s leadership in novel-novel combination treatment strategiesUpdated overall survival data for gotistobart from the PRESERVE-003 Phase 3 clinical trial will add to the growing body of evidence for this chemotherapy-free treatment approach in the second- and later-line treatment of advanced squamous non-small cell lung cancer following prior immunotherapyBioNTech is advancing a diversified development program in lung cancer treatment spanning more than 16 ongoing clinical trials across subtype
BNTX FAQ
7 questionsWhat does BioNTech SE do?
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen...Where does BNTX stock trade?
BioNTech SE (BNTX) is listed on NASDAQ.What sector and industry is BNTX in?
BioNTech SE operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did BioNTech SE go public?
BioNTech SE (BNTX) completed its IPO in 2019.What are analysts saying about BNTX?
BioNTech SE has had 8 recent analyst actions on file. The most recent action was from Argus: Hold on 2026-10-08.What companies are similar to BNTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare BNTX side-by-side with any of them on Quantisnow.How can I track BNTX on Quantisnow?
Quantisnow aggregates BioNTech SE's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BNTX to receive live email and push alerts on every new disclosure.